Tenax Therapeutics, Inc.
TENX
Rank in Stocks
#22985
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated... Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Share Price
$1.78
Last synced: 2026-11-09
Market Cap
$47.21M
Change (1 day)
5.33%
Change (1 year)
-74.54%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tenax Therapeutics, Inc. (TENX)
Category
Healthcare
Operating Margin for Tenax Therapeutics, Inc. (TENX)
Operating Margin as of November 2026 TTM: 0.00%
According to Tenax Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Tenax Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -31,729.59% | 442.91% |
| 2013 | -5,844.34% | 1,289.89% |
| 2012 | -420.49% | -78.77% |
| 2011 | -1,980.61% | -39.56% |
| 2010 | -3,276.78% | -84.78% |
| 2009 | -21,528.50% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | 7,344.95% | -24.04% |
| 2006 | 9,669.53% | 0.00% |
| 2005 | 9,669.53% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Tenax Therapeutics, Inc.'s operating margin
What was Tenax Therapeutics, Inc.'s operating margin in 2025?
In 2025, Tenax Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Tenax Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Tenax Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Tenax Therapeutics, Inc.'s operating margin compare with similar companies?
Tenax Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.